Conclusion
After ASUC responded to IVS, patients presented a slightly higher risk of relapse compared to what was expected from the overall UC population. More importantly, almost two-thirds of patients experienced clinical relapse as a failure of the chosen maintenance therapy, suggesting a need for a more ambitious strategy after ASUC responds to IVS. Early and complete response to IVS and the use of anti-TNF were predictors of better outcome in this setting. Prospective studies are needed to confirm our results.
Acknowledgement
Declaration of personal interests
Matthieu Allez has received honoraria from Novo Nordisk, MSD, Abbvie, Ferring, Genentech, Janssen, Pfizer, GSK, Hospira, UCB, Novartis, Takeda and Mayolo-Spindler. Laurent Beaugerie received consulting fees from Janssen, Pfizer and Allergan, lecture fees from Abbvie, Janssen, MSD, Ferring Pharmaceuticals, Mayoly-Spendler, Takeda and Tillots, and research support from Abbott, Ferring Pharmaceuticals, Hospira-Pfizer, Janssen, MSD, Takeda and Tillots. Jean-Marc Gornet has received honoraria from Abbvie, Janssen, Takeda, Tillotts Pharma, Sanofi and Amgen. Aurelien Amiot received consulting fees from Abbvie, Hospira, Takeda, Gilead and Biocodex as well as lecture fees and travel accommodations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Takeda and MSD. This author also received advisory board fees from Gilead, Takeda and Abbvie. No conflict of interest is claimed by the remaining authors.
Authorship
Guarantor of the article
Pr Aurelien Amiot.
Aliment Pharmacol Ther. 2020;51(11):1096-1104. © 2020 Blackwell Publishing
Comments